Evidence map›Paper›PMID 40605970›Full record

ArticleThe Lancet regional health. Western Pacific2025

Corrigendum to "A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients" The Lancet Regional Health-Western Pacific, Volume 55 (2025), 101464.

Yuji Hiromatsu, Eri Ishikawa, Ai Kozaki, Yasuhiro Takahashi, Mika Tanabe, Ken Hayashi, Yukihiro Imagawa, Kazutoyo Kaneda, Masashi Mimura, Xiaoxian Dai and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Yuji HiromatsuDiabetes, Thyroid and Endocrine Center, Shin Koga Hospital, 120 Tenjin-cho, Kurume, Fukuoka, 830-8577, Japan.
Eri IshikawaKozawa Eye Hospital and Diabetes Center, 246-6 Yoshizawa-cho, Mito-shi, Ibaraki, 310-0845, Japan.
Ai KozakiOlympia Eye Hospital, 2-18-12 Jinguumae, Shibuya-ku, Tokyo, 150-0001, Japan.
Yasuhiro TakahashiDepartment of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Mika TanabeDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Ken HayashiHayashi Eye Hospital, 4-23-35 Hakataekimae, Hakata-ku, Fukuoka, 812-0011, Japan.
Yukihiro ImagawaOculoplastic Surgery Center, Department of Ophthalmology, Osaka Kaisei Hospital, 1-6-10 Miyahara, Yodogawa-ku, Osaka, 532-0003, Japan.
Kazutoyo KanedaMiyazaki Chuo Eye Hospital, 3-6-21 Shimizu, Miyazaki-shi, Miyazaki, 880-0021, Japan.
Masashi MimuraOculoplastic Surgery Center, Department of Ophthalmology, Osaka Kaisei Hospital, 1-6-10 Miyahara, Yodogawa-ku, Osaka, 532-0003, Japan.
Xiaoxian DaiAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA.
Tomoko HayashidaAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320-1799, USA.
Takashi AkamizuKuma Hospital, 8-2-35 Shimoyamate-dori, Chuo-ku, Kobe, 650-0011, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.lanwpc.2025.101464.].

Identifiers

PMID40605970
PMCPMC12220065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.